Meningococcal Vaccines Market

Meningococcal Vaccines Market (Type: Polysaccharide, Conjugate Vaccines, Combination Vaccines, Men B Vaccine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Meningococcal Vaccines Market Outlook 2031

  • The market was valued at US$ 4.2 Bn in 2021
  • It is estimated to expand at a CAGR of 9.4% from 2022 to 2031 and to be worth $9.2 billion by the end of 2031.

Analysts’ Viewpoint on Market Scenario

High rate of adoption of meningococcal vaccine can be ascribed to the rise in awareness about the treatment avenues of meningococcal meningitis. This rare disease can lead to serious complications; it has a high fatality rate when left untreated. This type of meningitis is spread through contact with respiratory droplets and may have asymptomatic carriers.

It also causes an infection in the lining of the brain as well as the spinal cord. Increase in number of ongoing clinical programs for meningococcal vaccines at various stages of development around the world provides significant opportunities for market participants.

Companies focusing on assessing the potential of existing meningococcal vaccines for expanded age indications are likely to consolidate their position in the market. Moreover, rise in marketing approvals around the world is driving the global market.

meningococcal vaccines market

Market Overview

Meningococcal vaccines are used to prevent diseases such as meningitis, meningococcemia, and septicemia caused due to N. meningitides. Meningococcal disease, especially meningococcal meningitis, is highly infectious among individuals or communities.

Several meningococcal serogroups have been identified to date; of these, serogroups A, B, C, Y, and W-135 are the most prominent ones causing the infection.

Rise in prevalence of meningococcal meningitis has recently emerged as a public health concern. Several meningococcal infection treatment options are available around the world; however, the disease still claims several lives.

Meningococcal disease is spread through contact with secretions from the nose and throat (saliva or spit). Kissing, sharing silverware, drinking from the same container, sharing a cigarette or lipstick, coughing, and having close social contact (living in the same house) are examples of how the disease spreads. Vaccination is one of the most effective ways to prevent meningococcal disease.

Request a sample to get extensive insights into the Meningococcal Vaccines Market

Rise in Prevalence of Meningitis to Drive Global Meningococcal Vaccines Market

Meningococcal disease is infrequent; however, it has a fatality rate between 5% and 15%. If left untreated, it frequently leads to serious complications. Meningococcal meningitis causes an infection of the brain and spinal cord lining. It has the potential to cause large epidemics and endemics.

Each year, approximately 10 to 15 of every 100 people infected with meningococcal disease die. One in every five survivors is likely to suffer from permanent disabilities such as deafness, brain damage, limb loss, or seizures. Hence, demand for meningitis vaccines is increasing around the globe.

Increase in Awareness about Disease and Growth in Marketing Approvals to Boost Market

The National Meningitis Association (NMA) encourages collaboration by offering opportunities to work with government agencies, corporations, and other non-profit organizations in order to raise awareness about meningococcal disease, its prevention, and the critical need for immediate treatment after diagnosis. Increase in coverage rate of immunization programs around the world is likely to increase access to vaccines.

The Meningitis Foundation of America (MFA) is a non-profit organization that provides information and support to people who suffer from meningitis. The foundation also aims to raise public and medical awareness about the early symptoms of meningitis. Thus, the meningococcal vaccines market is estimated to expand at a steady pace during the forecast period.

Request a custom report on Meningococcal Vaccines Market

Rise in Sale of Meningococcal Conjugate Vaccines in Developing Countries to Fuel Market

Based on type, the conjugate vaccine segment is projected to dominate the market and account for 62% share by 2031. The benefits of meningococcal conjugate vaccines, such as long-lasting immunity, immunologic memory, avidity, and herd immunity, are driving sales. This trend is expected to continue during the forecast period.

Conjugate vaccines are extensively used in mass vaccination campaigns in affected areas such as Africa. Moreover, they have the ability to increase antibody persistence.

Various meningococcal conjugate vaccine programs have been introduced around the world over the last few decades. The vaccine has significantly reduced the incidence of meningococcal disease since 2010.

The recently introduced serogroup C conjugate vaccine is safe and effective even in the youngest children. Vaccines against group B meningococci have shown modest efficacy in both children and adults.

Government Support and High R&D investments Boosting Market in North America

North America dominated the global meningococcal vaccines market in 2021. The market in the region is anticipated to expand at a notable CAGR from 2022 to 2031. Government recommendations and support, and high R&D investments are driving the market in North America.

The U.S. is expected to be a prominent market for meningococcal vaccines in North America due to the rise in disease awareness and improved health care infrastructure in the country.

Meningococcal disease has been declining in the U.S. since the 1990s. According to the Centers for Disease Control and Prevention (CDC), approximately 350 cases of meningococcal disease were reported in 2017. Furthermore, awareness among the general public is increasing.

The meningococcal vaccines market in Asia Pacific is projected to grow at a rapid pace due to the presence of a large population, improved access to health care systems, and increase in awareness about the meningococcal disease in the region.

Analysis of Key Players

The global meningococcal vaccines market is fragmented, with a large number of large-scale vendors controlling a majority of the share. Most of the firms are investing significantly in comprehensive research and development activities.

Expansion of product portfolios and mergers and acquisitions are major strategies adopted by key players. Market players are focusing on key trends in meningococcal vaccines with the help of recent R&D insights.

Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd. are the prominent entities operating in the market.

Each of these players has been profiled in the meningococcal vaccines market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments.

Key Developments in Global Meningococcal Vaccines Market

  • In January 2022, CanSino Biologics Inc. announced that the National Medical Products Administration of China ("NMPA") approved its ACYW135 Meningococcal Conjugate Vaccine (MCV4, trade name: MenhyciaTM), making it the first of its kind in China. MenhyciaTM covalently binds common pathogenic meningococcal serogroups A, C, W135, and Y to the carrier protein CRM197.
  • In April 2020, The U.S. FDA approved a Biologics License Application for Sanofi's MenQuadfiTM meningococcal conjugate vaccine for the prevention of invasive meningococcal disease in children aged two years and older. MenQuadfi was developed to elicit and demonstrate a high immune response across all four serogroups for a wide range of ages, and it was well tolerated. MenQuadfi is designed to protect a broader age range.
  • In April 2018, Pfizer Inc announced that TRUMENBA (Meningococcal Group B Vaccine) received FDA Breakthrough Therapy designation for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children aged 1 to 9 years. This is the first time a MenB vaccine has been designated as a Breakthrough Therapy to help protect children as young as one year old. TRUMENBA was previously designated as a Breakthrough Therapy in 2014 for the prevention of MenB in adolescents and young adults aged 10 to 25 years, and later that year received the FDA approval as the first MenB vaccine in the U.S.

Meningococcal Vaccines Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 4.2 Bn

Market Forecast Value in 2031

US$ 9.2 Bn

Growth Rate (CAGR)

9.4%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Polysaccharide
      • Menomune
      • Mencevax
      • NmVac4
      • Others
    • Conjugate Vaccines
      • Menactra
      • Menveo
      • NeisVac-C
      • Nimenrix
      • Meningitec
      • Menjugate
      • MenAfriVac
      • NmVac4-DT
    • Combination Vaccines
      • MenHibrix
      • Menitorix
    • Men B Vaccines
      • Bexsero
      • Trumenba
  • End-user
    • Retail Pharmacies
    • Hospital Pharmacies
    • Others (online pharmacies, drug stores)

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia & CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC
  • South Africa

Companies Profiled

  • Sanofi SA
  • Novartis International
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Nuron Biotech
  • JN-International Medical Corporation
  • Serum Institute of India Ltd
  • Baxter International
  • Biomed Pvt. Ltd

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global meningococcal vaccines market in 2021?

It was valued at US$ 4.2 Bn in 2021

How big will be the market in 2031?

It is projected to reach US$ 9.2 Bn by 2031

What will be the CAGR of the global market during the forecast period (2022-2031)?

It is anticipated to record a CAGR of 9.4% from 2022 to 2031

What are the prominent trends impacting the market growth?

Growth in prevalence of meningitis, rise in disease awareness, and increase in marketing approvals are prominent trends driving the market

What was the market share of the leading segment of the global market in 2021?

The conjugate vaccine type segment held over 60% share of the global market in 2021

Which region would hold a major market share during the forecast period?

North America is expected to hold a major share of the global market during the forecast period

Who are the prominent players in the meningococcal vaccines industry?

Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Meningococcal Vaccines Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2021–2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Regulatory Scenario by Region/globally

        5.3. Covid-19 Impact analysis

    6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

            6.3.1. Polysaccharide

                6.3.1.1. Menomune

                6.3.1.2. Mencevax

                6.3.1.3. NmVac4

                6.3.1.4. Others

            6.3.2. Conjugate Vaccines

                6.3.2.1. Menactra

                6.3.2.2. Menveo

                6.3.2.3. NeisVac-C

                6.3.2.4. Nimenrix

                6.3.2.5. Others

            6.3.3. Combination Vaccines

                6.3.3.1. MenHibrix

                6.3.3.2. Menitorix

            6.3.4. Men B Vaccines

                6.3.4.1. Bexsero

                6.3.4.2. Trumenba

        6.4. Global Meningococcal Vaccines Market Attractiveness, by Type

    7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

            7.3.1. Retail Pharmacies

            7.3.2. Hospital Pharmacies

            7.3.3. Others (online pharmacies, drug stores)

        7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user

    8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Global Meningococcal Vaccines Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Global Meningococcal Vaccines Market Attractiveness, by Country/Region

    9. North America Meningococcal Vaccines Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

            9.2.1. Polysaccharide

                9.2.1.1. Menomune

                9.2.1.2. Mencevax

                9.2.1.3. NmVac4

                9.2.1.4. Others

            9.2.2. Conjugate Vaccines

                9.2.2.1. Menactra

                9.2.2.2. Menveo

                9.2.2.3. NeisVac-C

                9.2.2.4. Nimenrix

                9.2.2.5. Others

            9.2.3. Combination Vaccines

                9.2.3.1. MenHibrix

                9.2.3.2. Menitorix

            9.2.4. Men B Vaccines

                9.2.4.1. Bexsero

                9.2.4.2. Trumenba

        9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

            9.3.1. Retail Pharmacies

            9.3.2. Hospital Pharmacies

            9.3.3. Others (online pharmacies, drug stores)

        9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2021–2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. North America Meningococcal Vaccines Market Attractiveness Analysis

            9.5.1. By Type

            9.5.2. By End-user

            9.5.3. By Country

    10. Europe Meningococcal Vaccines Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

            10.2.1. Polysaccharide

                10.2.1.1. Menomune

                10.2.1.2. Mencevax

                10.2.1.3. NmVac4

                10.2.1.4. Others

            10.2.2. Conjugate Vaccines

                10.2.2.1. Menactra

                10.2.2.2. Menveo

                10.2.2.3. NeisVac-C

                10.2.2.4. Nimenrix

                10.2.2.5. Others

            10.2.3. Combination Vaccines

                10.2.3.1. MenHibrix

                10.2.3.2. Menitorix

            10.2.4. Men B Vaccines

                10.2.4.1. Bexsero

                10.2.4.2. Trumenba

        10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

            10.3.1. Retail Pharmacies

            10.3.2. Hospital Pharmacies

            10.3.3. Others (online pharmacies, drug stores)

        10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis

            10.5.1. By Type

            10.5.2. By End-user

            10.5.3. By Country/Sub-region

    11. Asia Pacific Meningococcal Vaccines Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

            11.2.1. Polysaccharide

                11.2.1.1. Menomune

                11.2.1.2. Mencevax

                11.2.1.3. NmVac4

                11.2.1.4. Others

            11.2.2. Conjugate Vaccines

                11.2.2.1. Menactra

                11.2.2.2. Menveo

                11.2.2.3. NeisVac-C

                11.2.2.4. Nimenrix

                11.2.2.5. Others

            11.2.3. Combination Vaccines

                11.2.3.1. MenHibrix

                11.2.3.2. Menitorix

            11.2.4. Men B Vaccines

                11.2.4.1. Bexsero

                11.2.4.2. Trumenba

        11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

            11.3.1. Retail Pharmacies

            11.3.2. Hospital Pharmacies

            11.3.3. Others (online pharmacies, drug stores)

        11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis

            11.5.1. By Type

            11.5.2. By End-user

            11.5.3. By Country/Sub-region

    12. Latin America Meningococcal Vaccines Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

            12.2.1. Polysaccharide

                12.2.1.1. Menomune

                12.2.1.2. Mencevax

                12.2.1.3. NmVac4

                12.2.1.4. Others

            12.2.2. Conjugate Vaccines

                12.2.2.1. Menactra

                12.2.2.2. Menveo

                12.2.2.3. NeisVac-C

                12.2.2.4. Nimenrix

                12.2.2.5. Others

            12.2.3. Combination Vaccines

                12.2.3.1. MenHibrix

                12.2.3.2. Menitorix

            12.2.4. Men B Vaccines

                12.2.4.1. Bexsero

                12.2.4.2. Trumenba

        12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

            12.3.1. Retail Pharmacies

            12.3.2. Hospital Pharmacies

            12.3.3. Others (online pharmacies, drug stores)

        12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Latin America Meningococcal Vaccines Market Attractiveness Analysis

            12.5.1. By Type

            12.5.2. By End-user

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2021–2031

            13.2.1. Polysaccharide

                13.2.1.1. Menomune

                13.2.1.2. Mencevax

                13.2.1.3. NmVac4

                13.2.1.4. Others

            13.2.2. Conjugate Vaccines

                13.2.2.1. Menactra

                13.2.2.2. Menveo

                13.2.2.3. NeisVac-C

                13.2.2.4. Nimenrix

                13.2.2.5. Others

            13.2.3. Combination Vaccines

                13.2.3.1. MenHibrix

                13.2.3.2. Menitorix

            13.2.4. Men B Vaccines

                13.2.4.1. Bexsero

                13.2.4.2. Trumenba

        13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2021–2031

            13.3.1. Retail Pharmacies

            13.3.2. Hospital Pharmacies

            13.3.3. Others (online pharmacies, drug stores)

        13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-region, 2021–2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis

            13.5.1. By Type

            13.5.2. By End-user

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competition Matrix (by tier and size of companies)

        14.2. Market Share Analysis, by Company, 2021

        14.3. Company Profiles

            14.3.1. Sanofi SA

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. SWOT Analysis

                14.3.1.4. Strategic Overview

            14.3.2. Novartis International

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. SWOT Analysis

                14.3.2.4. Strategic Overview

            14.3.3. GlaxoSmithKline plc

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. SWOT Analysis

                14.3.3.4. Strategic Overview

            14.3.4. Pfizer Inc.

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. SWOT Analysis

                14.3.4.4. Strategic Overview

            14.3.5. Nuron Biotech.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. SWOT Analysis

                14.3.5.4. Strategic Overview

            14.3.6. JN-International Medical Corporation.

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. SWOT Analysis

                14.3.6.4. Strategic Overview

            14.3.7. Serum Institute of India Ltd

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. SWOT Analysis

                14.3.7.4. Strategic Overview

            14.3.8. Baxter International

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. SWOT Analysis

                14.3.8.4. Strategic Overview

    List of Tables

    Table 01: Global Meningococcal Vaccine Market Pipeline Analysis

    Table 02: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

    Table 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide Meningococcal Vaccines, 2022–2031

    Table 04: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Meningococcal Vaccines, 2022–2031

    Table 05: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Meningococcal Vaccines, 2022–2031

    Table 06: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Meningococcal Vaccines, 2022–2031

    Table 07: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

    Table 08: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Region, 2022–2031

    Table 09: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country, 2022–2031

    Table 10: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

    Table 11: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

    Table 12: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

    Table 13: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

    Table 14: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

    Table 15: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

    Table 16: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

    Table 17: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

    Table 18: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

    Table 19: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

    Table 20: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

    Table 21: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

    Table 22: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

    Table 23: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

    Table 24: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

    Table 25: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

    Table 26: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

    Table 27: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

    Table 28: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

    Table 29: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

    Table 30: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

    Table 31: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

    Table 32: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

    Table 33: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

    Table 34: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

    Table 35: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

    Table 36: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

    Table 37: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Country/Sub-region, 2022–2031

    Table 38: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Type, 2022–2031

    Table 39: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Polysaccharide, 2022–2031

    Table 40: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Conjugate Vaccines, 2022–2031

    Table 41: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Combination Vaccines, 2022–2031

    Table 42: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by Men B Vaccines, 2022–2031

    Table 43: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, by End-user, 2022–2031

    List of Figures

    Figure 01: Global Meningococcal Vaccines Market Size (US$ Bn) and Distribution, by Region, 2022 and 2031

    Figure 02: Market Snapshot of Global Meningococcal Vaccines Market

    Figure 03: Global Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

    Figure 04: Market Value Share, by Type, 2021

    Figure 05: Market Value Share, by End-user, 2021

    Figure 06: Market Value Share, by Region, 2021

    Figure 07: Global Meningococcal Vaccines Market Value Share Analysis, by Type, 2022 and 2031

    Figure 08: Global Meningococcal Vaccines Market Attractiveness, by Type2022–2031

    Figure 09: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by   Polysaccharide Vaccines, 2022–2031

    Figure 10: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Conjugate Vaccines, 2022–2031

    Figure 11: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, Combination Vaccines, 2022–2031

    Figure 12: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Men B Vaccines, 2021

    Figure 13: Global Meningococcal Vaccines Market Value Share Analysis, by End-user, 2022 and 2031

    Figure 14: Global Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

    Figure 15: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2022–2031

    Figure 16: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2022–2031

    Figure 17: Global Meningococcal Vaccines Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022–2031

    Figure 18: Global Meningococcal Vaccines Market Value Share (%), by Region, 2022 and 2031

    Figure 19: Global Meningococcal Vaccines Market Attractiveness, by Region2022–2031

    Figure 20: North America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

    Figure 21: North America Meningococcal Vaccines Market Value Share (%), by Country, 2022 and 2031

    Figure 22: North America Meningococcal Vaccines Market Attractiveness, by Country2022–2031

    Figure 23: North America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

    Figure 24: North America Meningococcal Vaccines Market Attractiveness, by Type2022–2031

    Figure 25: North America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

    Figure 26: North America Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

    Figure 27: Europe Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

    Figure 28: Europe Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031

    Figure 29: Europe Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031

    Figure 30: Europe Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

    Figure 31: Europe Meningococcal Vaccines Market Attractiveness, by Type2022–2031

    Figure 32: Europe Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

    Figure 33: Europe Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

    Figure 34: Asia Pacific Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

    Figure 35: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031

    Figure 36: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031

    Figure 37: Asia Pacific Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

    Figure 38: Asia Pacific Meningococcal Vaccines Market Attractiveness, by Type2022–2031

    Figure 39: Asia Pacific Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

    Figure 40: Asia Pacific Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

    Figure 41: Latin America Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

    Figure 42: Latin America Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031

    Figure 43: Latin America Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031

    Figure 44: Latin America Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

    Figure 45: Latin America Meningococcal Vaccines Market Attractiveness, by Type2022–2031

    Figure 46: Latin America Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

    Figure 47: Latin America Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

    Figure 48: Middle East & Africa Meningococcal Vaccines Market Value (US$ Bn) Forecast, 2022–2031

    Figure 49: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Country/Sub-region, 2022 and 2031

    Figure 50: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Country/Sub-region2022–2031

    Figure 51: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by Type, 2022 and 2031

    Figure 52: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by Type2022–2031

    Figure 53: Middle East & Africa Meningococcal Vaccines Market Value Share (%), by End-user, 2022 and 2031

    Figure 54: Middle East & Africa Meningococcal Vaccines Market Attractiveness, by End-user2022–2031

    Figure 55: Global Meningococcal Vaccines Market Share, by Company, 2018

    Figure 56: Baxter International, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016–2018

    Figure 57: Baxter International, Inc. Breakdown of Net Sales (%), by Region, 2018

    Figure 58: Pfizer Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2016–2018

    Figure 59: Pfizer Inc. Breakdown of Net Sales (%), by Region, 2018

    Figure 60: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2021

    Figure 61: Novartis AG Breakdown of Net Sales, by Region, 2021

    Figure 62: Novartis AG Breakdown of Net Sales, by Business Segment, 2021

    Figure 63: Novartis AG Breakdown of Net Sales, by Innovative Medicines Business Units, 2021

    Figure 64: Sanofi S.A Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2021

    Figure 65: Sanofi S.A Breakdown of Net Sales (%), by Business Segment, 2021

    Figure 66: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2021

    Figure 67: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2021

Copyright © Transparency Market Research, Inc. All Rights reserved